Close Menu

More articles about Disease Areas

The firm CE marked its RespiFinder 2Smart kit for SARS-CoV-2 and MERS-CoV testing, as well as the RealAccurate Quadriplex Flu/COVID-19 PCR kit.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.

Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.

Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.

The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.

In a conversation at the Association for Molecular Pathology meeting, the directors touched on topics such as test allocation and staffing and reagent shortages.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

The company plans to increase the capacity of its CLIA-certified laboratory to about 100,000 SARS-CoV-2 tests per day by the end of 2020.

The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.

The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.

The companies aim to identify biomarkers that can be used to diagnose early-onset Parkinson's disease, as well as track disease progression.

The researchers created a test-on-a-chip technology that takes about 35 minutes to produce a result, and may partner with Ford to produce the chips.

TwinStrand's duplex sequencing correction technology can detect ultra-low frequency DNA mutations that are otherwise often obscured by technical noise.

One of the tests is customized for use on Bioneer's automated ExiStation instrument, while the other is compatible with various standard PCR systems.

The firm said the assay is an enhanced version of a test it made available this summer that measures the amount of neutralizing antibodies to SARS-CoV-2.

The loop-mediated isothermal amplification test runs on a battery-powered device to provide self-testing individuals with results in approximately 30 minutes.

DiaSorin aims to develop a fully automated, chemiluminescent immunoassay for the semiquantitative detection of IgG antibodies against the SARS-CoV-2 virus.

The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.

The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.

Pages